Your browser doesn't support javascript.
loading
Potential for palivizumab interference with commercially available antibody-antigen based respiratory syncytial virus diagnostic assays.
Deming, Damon J; Patel, Nita; McCarthy, Michael P; Mishra, Lalji; Shapiro, Alan M; Suzich, JoAnn A.
Afiliación
  • Deming DJ; From the *United States Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drugs, Office of Antimicrobial Products, Division of Antiviral Products, Silver Spring; and †MedImmune, LLC, Gaithersburg, MD.
Pediatr Infect Dis J ; 32(10): 1144-6, 2013 Oct.
Article en En | MEDLINE | ID: mdl-23584584
Palivizumab is a monoclonal antibody indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus infection in infants. The potential for palivizumab to interfere with commercially available respiratory syncytial virus diagnostic tests was demonstrated. Negative test results in palivizumab-treated subjects should be interpreted with caution and confirmed by a nucleic acid amplification-based assay.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus Sincitiales Respiratorios / Virología / Inmunoensayo / Infecciones por Virus Sincitial Respiratorio / Anticuerpos Monoclonales Humanizados Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Pediatr Infect Dis J Asunto de la revista: DOENCAS TRANSMISSIVEIS / PEDIATRIA Año: 2013 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus Sincitiales Respiratorios / Virología / Inmunoensayo / Infecciones por Virus Sincitial Respiratorio / Anticuerpos Monoclonales Humanizados Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Pediatr Infect Dis J Asunto de la revista: DOENCAS TRANSMISSIVEIS / PEDIATRIA Año: 2013 Tipo del documento: Article Pais de publicación: Estados Unidos